Johnson & Johnson purchased a gene therapy for X-linked retinitis pigmentosa from MeiraGTx for $65 million upfront, the biotech announced Thursday. The deal, which also comes with a commercial supply agreement, could be worth up to $415 million, including another...
Pictured: Novartis campus in Switzerland/iStock, Michael Derrer Fuchs Novartis is discontinuing the development of GT005, a mid-stage investigational gene therapy being developed for geographic atrophy secondary to dry age-related macular degeneration. The...
